AI
ORIC icon

Atom Investors’s Oric Pharmaceuticals ORIC Stock Holding History

Atom Investors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.87M Sell
226,804
-63,158
-22% -$717K 0.21% 171
2025
Q4 		$2.37M Buy
289,962
+147,361
+103% +$1.7M 0.19% 169
2025
Q3 		$1.71M Sell
142,601
-110,052
-44% -$1.16M 0.13% 186
2025
Q2 		$2.56M Buy
252,653
+41,947
+20% +$282K 0.23% 128
2025
Q1 		$1.18M Buy
210,706
+134,064
+175% +$1.17M 0.14% 187
2024
Q4 		$619K Buy
+76,642
New +$703K 0.08% 298
2024
Q3 		– Sell
-36,901
Closed -$261K – 572
2024
Q2 		$261K Buy
36,901
+5,506
+18% +$49.3K 0.03% 394
2024
Q1 		$432K Sell
31,395
-9,152
-23% -$109K 0.05% 359
2023
Q4 		$373K Buy
40,547
+6,306
+18% +$45.6K 0.07% 323
2023
Q3 		$207K Sell
34,241
-11,657
-25% -$95.5K 0.05% 374
2023
Q2 		$356K Sell
45,898
-19,881
-30% -$113K 0.14% 160
2023
Q1 		$375K Sell
65,779
-58,042
-47% -$303K 0.2% 126
2022
Q4 		$729K Sell
123,821
-6,720
-5% -$22.7K 0.36% 69
2022
Q3 		$418K Buy
130,541
+51,819
+66% +$207K 0.15% 163
2022
Q2 		$353K Buy
+78,722
New +$314K 0.15% 138

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Atom Investors's ORIC Position: Q1 2026 in Review

Atom Investors reduced its Oric Pharmaceuticals (ORIC) stake by 22% in Q1 2026, selling an estimated $717K and leaving 226,804 shares worth $2.87M. The position accounts for 0.21% of the portfolio, ranked #171.

Atom Investors first reported a position in ORIC in Q2 2022 and has held it in 15 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Atom Investors held 226,804 shares of Oric Pharmaceuticals worth $2.87M as of Q1 2026.
  • Atom Investors sold 63,158 Oric Pharmaceuticals shares in Q1 2026, an estimated $717K.
  • Oric Pharmaceuticals made up 0.21% of Atom Investors's portfolio in Q1 2026, its #171 holding.
  • Atom Investors first reported a position in Oric Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.